




Transformative crop protection technology platform

May 2024




Shaping the future of sustainable and safe food supply



AgTech company developing novel protein-based solutions to protect crops against pests and diseases


Antibody-based technology already successfully applied in pharma

Regulatory review ongoing in the US and EU for EVOCA^{TM,2}, Biotallys' first product aiming to offer fruit & vegetable growers a new tool to fight major fungal diseases




Notes: 1. As of January 2024; 2. EvocaTM is pending registration. This product is not currently registered for sale or use in the US, the EU or elsewhere, and is not being offered for sale

Proven technology rapidly transforming agriculture




Note: 1. Fungicide Resistance Action Committee; 2. Modes of Action

CAGR of biological solutions forecasted to outpace industry



- Global Insecticide & Fungicide market projected to grow at 4.5% CAGR to 2030 to reach \$51.31 B
- Global biofungicide and bioinsecticide growth projected at 12% CAGR reaching \$10.26B combined
- Global share of biological solutions projected to gain 7% during the period to achieve 20% share of the total market
- Focus on biologicals evident by M&A activity over recent years

Selected M&A activity



Sources: Company information, Dunham Trimmer, Markets and Markets, Fortune Business Insights

Critical need for new methods of crop protection

Combat resistance to traditional synthetic portfolio



- 13 fungal modes of action, of which most have developed medium to high resistance issues from target
- Over 500 distinct pest species have developed resistance to insecticides

Meet increasing demand for sustainably sourced food from consumers



- Produce food with a softer environmental and synthetic chemistry footprint
- Estimated that 80 percent of the projected additional food demand by 2050 will come from plant products²


Offset continuous decline in available active ingredients due to regulatory restrictions




- 162 countries have banned 460 pesticide active ingredients, and the list continues to grow¹
- US is currently using 72 pesticides that are currently banned, or will be banned in Europe



Biotallys is set to enter the market, fully prepared for commercial deployment



Biotalys AGROBODY Platform unleashes a vast array of combinations of MoAs for superior agricultural efficacy



AGROBODY Foundry 2.0 – from platform validation to a next generation of the technology platform



Benefits of AGROBODY 2.0

1. Increased potency


- ⊗ Lower application rates
- ⊗ Improved COGS
- ⊗ Broader market penetration
- ⊗ Improved profitability

2. Defined Mode of Action

- ⊗ Improved ability to combine MoA's
- ⊗ Increase efficiency of development work
- ⊗ Enhance regulatory dossier & approval timeline

3. Anticipate upcoming resistance

- ⊗ Combined MoA's decrease likelihood of resistance
- ⊗ Anticipate on changes in pathogen by using bioinformatics & AI technology





Innovative pipeline of biofungicides and bioinsecticides

Program	Target	Market	Discovery	Early Development	Late Development	Registration	Partnership Agreement
EVOCA 1 st Gen	Botrytis, powdery mildew	High-value fruits & vegetables	●	●	●	--- Pilot product	biobeT SUSTAINABLE CROP MANAGEMENT
EVOCA Next Gen	Botrytis, powdery mildew	High-value fruits & vegetables	●	●	●		novonisis biobeT SUSTAINABLE CROP MANAGEMENT
BioFun-6	Botrytis, powdery mildew, Anthracnosis	High-value fruits & vegetables	●	→			Discussions ongoing
BioFun-7	Cercospora spp. (leafspot disease)	Cowpeas and other legumes	●	→			BILL & MELINDA GATES foundation
BioFun-4	Oomycetes (water mold)	Potatoes / High-value fruits & vegetables	●	→			Discussions ongoing
BioIns-2	Key insect pests	Non-disclosed	●	→			syngenta

1 new program per year resulting in +10 AGROBODY biocontrols to be launched on the market between 2025 and 2040

Distribution agreement Manufacturing agreement Research agreement


...With the potential to unleash an array of combinations of different MoAs, opening up major market growth vectors



Biotallys is developing +10 different modes of action in the next decade, with the potential to combine these MoAs into different products and offer a multitude of unique AGROBODY biocontrol solutions by then

Source: Data based on company's own estimates

Platform optimizations delivering a profitable pipeline and ensuring a sustainable and safe food supply



Source: 1. Company's estimates

EVOCA™: A novel tool for biocontrol¹

Effective rotation product, as demonstrated in global field trial program³

Contact activity for preventive control of grey mold (*Botrytis cinerea*) and powdery mildew

New mode-of-action for resistance management: replacement of conventional chemicals in rotation programs

Supports residue reduction in rotation programs³




Convenience, storability and reliability of traditional chemicals²

Designed to be safe for workers, consumers & the environment

Regulatory review ongoing in the US and EU

Introduction crops: Vines and high-value fruit & vegetables




  **Evoca wins World BioProtection Award 2022 for best biofungicide product** 

Note: 1. Evoca™ is pending registration. This product is not currently registered for sale or use in the United States, the EU or elsewhere, and is not being offered for sale; 2. Formulated as water soluble granules
Source: 3: Biotallys data

Since 2017 EVOCA™ consistently performed as good or better than synthetic counterparts in field trials

Independent trials executed by designated growers





EVOCA™ has been tested in over 600 trials since 2017 across numerous crops, demonstrating consistent performance over various growing seasons and fighting resistance, providing growers a competitive alternative to synthetic counterparts

Science and Technology Partners



EVOCA™ confirms in independent field trials US

Independent trials executed by UC Davis and Florida University



Highlights

- ⊕ True replacer for chemical products as well as a top performing biological option to combat Botrytis in grapes
- ⊕ Proved consistent protection against Botrytis in a variety of application programs for grapevines
- ⊕ Rotation programs including EVOCA provided equivalent protection against powdery mildew as chemical-only rotations

The Biotalys and Novonesis partnership unleashes production breakthroughs, propelling to commercialization



- ⊕ **EVOCA NG** is advanced to the **final stage of development together with Novonesis**, a global leader in biosolutions
- ⊕ **Novonesis** is appointed as **global manufacturer** of EVOCA NG, leveraging its key fermentation capabilities
- ⊕ **Novonesis** and Biotalys will co-commercialize EVOCA NG, with Novonesis covering all markets in Europe and South Africa (outside of covered crops and field berries), with potential other markets
- ⊕ Biotalys and Novonesis will **explore future collaborations** involving the AGROBODY™ technology platform in combination with their proprietary enzyme platform

Multiple strategic options for collaboration monetization¹




Deal structure customized to partner capabilities, resources and interests, resulting in either more front or back loaded deals



Note 1. : Biotallys further explores a broad range of partnerships along the food value chain with established players including at crop protection and around/post harvest stages

EVOCA regulatory approval process continues to advance



Regulatory packages filed in US and EU



Novel nature of the technology requires in-depth review, but also sets standard for future approvals of protein-based biocontrols



Ongoing dialogue with agencies to clarify outstanding items















Trials executed in the following regions



AGROBODY platform is designed to allow for broadening scope and applicability

AGROBODY™ Biocontrol by biotalys

Use segments		Crops	Use segments		Geographies	
	Fungicides ✓	 Fruits & Vegetables ✓		Pre-harvest applications ✓	 US ✓	
	Insecticides ✓	 Rice ↻		Post-harvest applications ✓	 EU ✓	
		 Corn ↻			 South America ↻	
		 Cereals ↻			 Australia /New-Zealand ↻	

Biotallys' AGROBODY platform stands out for its versatility and adaptability, serving as the bedrock for expanding and enhancing agricultural solutions to benefit growers and ecosystems alike

Adopting a cost-efficient targeted approach to research & development

Corporate Finance Objectives

- ⊕ Maximize cash inflow
- ⊕ Minimize cash outflow without impacting future growth

Quality of earnings

- ⊕ Monetizing the platform via Milestone / License / Royalty agreements

Key finance metrics

- ⊕ Restructuring and tighter financial control in 2023 led to:
 - ⊕ Increased efficiency & effectiveness
 - ⊕ Decreased cash burn by ~25% from 2022 to 2024
 - ⊕ Extended cash runway by 10 months over the last year, split between savings and new funding
- ⊕ Optimized SG&A to continue to deliver on platform

In € thousand	December 31, 2023	December 31, 2022
Other operating income	2,611	2,949
Research and development expenses	(16,608)	(18,813)
General and administration expenses	(5,708)	(5,081)
Marketing expenses	(1,186)	(1,586)
Operating loss	(20,891)	(22,531)
Loss for the period	(20,510)	(22,731)
Basic and diluted loss per share (in EUR)	(0.65)	(0.74)
Net cash inflow (outflow) for the period	(12,521)	(22,017)
Cash and cash equivalents	21,570	34,096

Upcoming key milestones for Biotallys



EVOCA™ Registration

- ⦿ Obtain product approval for EVOCA in the U.S. & Europe, while exploring options to submit in other regions such as Latin America and South Africa



AGROBODY Foundry™ 2.0

- ⦿ Leverage platform to secure further strategic crop protection R&D collaborations
- ⦿ Upgrade platform capabilities towards exponential potency and costs targets
- ⦿ Expectation to initiate at least 1 new program per year on the AGROBODY Platform 2.0



Commercial Agreements

- ⦿ Finalize last stage of development of EVOCA NG with Novonosis
- ⦿ Enter into new partnership agreement for BioFun-6



Funding

- ⦿ Secure additional funding to continue the company's growth trajectory

Investment highlights



High growth-market and vast opportunity

Biotallys' innovative platform currently focuses on the highest growth segment in crop inputs, focusing on high-value fruits & vegetables with additional upside potential into other markets including post-harvest



Unique technology with leading ROIs

Biotallys pioneers cutting-edge technology, proven effective in the pharmaceutical sector, offering growers unparalleled crop protection alternatives with industry-leading ROIs



Capital efficient business model

Cost-efficient R&D focused on advancing novel solutions to unlock multiple new modes of action in fungicides and insecticides and producing these at competitive COGS



Multiple roads to market

Regulatory processes advancing in US and EU
Commercial agreements for production and marketing in place



Solid foundation

Led by experienced management team, board and scientific advisors
Continued cost management coupled with exploration of revenue streams from partnerships

Appendix



Experienced management and board



Kevin Helash
CEO



Douglas Minder
CFO



Carlo Boutton
CSO



Sophie Snijders
Head of HR




Toon Musschoot
Head of IR & Comms



Eva Van Hende
Head of Regulatory & Field Development



Simon E. Moroney
Chairman



Michiel van Lookeren Campagne
Independent Director



Piet Bevernage
Non-Executive Director



Johan Cardoen
Independent Director



Patrik Haesen
Non-Executive Director



Patrick Van Beneden
Non-Executive Director



Catherine Moukheibir
Independent Director



Markus Heldt
Independent Director



VP Investor Relations Bayer to join the Biotallys Board





Laura J. Meyer

Laura Meyer has >28 years of experience at Monsanto/Bayer

“I am passionate about agriculture and the demand for novel, sustainable solutions, like those offered by the AGROBODY technology platform, has never been greater.”

“I am eager to contribute to another wave of transformative technologies for farmers around the globe.”


Blockbuster strategy with small-molecules, broad-spectrum chemistry has run its course



- ### More regulatory, resistance & environmental pressure
- **EU bans on widely used fungicides** (example mancozeb (\$1,6b) and chlorotalonil (\$0,8 b) in 2021) **and insecticides** (example: oxamyl in 2024 and neonics in 2018)
 - **Resistance issues** growing in fungicides with cymoxanil, metalaxyl and strobilurin family
 - **Soil management issue** with copper oxides and other organic pesticides

Note: 1. Phillips McDougal Ag Industry Overview (2020)


Human resources



~65 staff
60/40 gender balance



16 PhD's



~39y average age

Biotallys is an ESG driven company

Food Loss

Offer new tools to protect our food



KPIs : Number of new MoAs, Number of application window expansion

Human Capital

Offer equal chances and growth



KPIs : Engagement, Attrition, Learning, Diversity

Environmental product Impact

Reduce agricultural impact overall



KPIs : Volume, Carbon footprint, product displaced

Innovation Management


Lead by scientific rigour




KPIs : Patents, Articles, grants, reporting



Biotalys puts everything in place to ensure its technology is strongly protected



IP strategy



- **Patents** and **proprietary know-how**
 - AGROBODY Foundry™ platform
 - Products incl. a.o. AGROBODY™ biocontrol sequences
- **Specific patent applications** relating to elements of the underlying technology platform
- Creation of **patent families** around the product pipeline
- Threat detection and mitigation via **active monitoring** of new patent applications

Disclaimer



This presentation, including the oral presentation (together, the “Materials”) has been prepared by the management of Biotallys NV (the “Company”). The Materials must be treated confidentially and may not be distributed, passed on or otherwise disclosed. The Materials serve information purposes only and do not constitute a prospectus or any offer for sale or subscription of, or solicitation or invitation to buy or subscribe for, any securities of the Company. The Company’s business, operations, financial situation and prospects are subject to risks and uncertainties. A description of the most important risks and uncertainties can be found in the Company’s annual report available on its website (www.Biotallys.com)

This presentation includes market share and industry data, which were obtained by the Company from industry publications, press releases, data published by government agencies, industry reports prepared by consultants and other market data providers and internal surveys. The third party sources the Company has used generally state that the information they contain has been obtained from sources believed to be reliable. Some of these third party sources also state, however, that the accuracy and completeness of such information is not guaranteed and that the projections they contain are based on significant assumptions. As the Company does not have access to the facts and assumptions underlying such market data, or statistical information and economic indicators contained in these third party sources, the Company is unable to verify such information and, while the Company believes it to be reliable, it cannot guarantee its accuracy or completeness.

In addition, certain information in this document is not based on published data obtained from independent third parties or extrapolations therefrom, but rather is based upon the Company’s best estimates, which are in turn based upon information obtained from trade and business organizations and associations, consultants and other contacts within the industries in which the Company operates, information published by its competitors and its own experience and knowledge of conditions and trends in the markets in which it operates. The Company cannot provide any assurance that any of the assumptions that it has made while compiling this data from third party sources are accurate or correctly reflect its position in the industry and none of its internal estimates have been verified by any independent sources. The Company makes no representation or warranty as to the accuracy or completeness of this information. The Company has not independently verified this information and, while the Company believes it to be reliable, it cannot guarantee its accuracy.

You are responsible for protecting yourself against viruses and other destructive items. You are accessing the Materials is at your own risk and it is your responsibility to take precautions to ensure that they are free from viruses or other items of a destructive nature.

The Materials are provided in conjunction with the oral presentation held by the Company and should not be taken out of context.

The information contained in the Materials is subject to change without prior notice. The presentation of the Materials (or any part hereof) shall not create any implication that there has been no change in the information contained in the Materials since the date hereof or that there has been no change in the business or financial position of the Company or its subsidiary since the date hereof. The Company does not undertake to provide any additional information, update or keep current information contained in the Materials, or to remedy any omissions in or from the Materials and any opinions expressed in the Materials are subject to change without prior notice. The foregoing is in any event without prejudice to the Company’s obligations under applicable law in relation to disclosure.

The Materials contain certain forward-looking statements, sometimes identified by the words “believes,” “expects,” “predicts,” “intends,” “projects,” “plans,” “estimates,” “aims,” “foresees,” “anticipates,” “targets,” and similar expressions, which speak only as at the date of the Materials. Such statements reflect current views with respect to future events and are subject to risks and uncertainties. Forward-looking statements are based on current plans, estimates, projections and expectations. These statements are based on certain assumptions that may prove to be erroneous. No representations or warranties, express or implied, are given as to the achievement or reasonableness of, and no reliance should be placed on, such forward-looking statements, including any projections, estimates forecasts or targets contained herein.

Nothing in this presentation constitutes an offer of securities for sale in the EEA, the United Kingdom, Switzerland, Japan, the United States or elsewhere. The securities of the Company are not registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”) and may not be offered, sold or otherwise transferred within the United States (as such term is defined in Regulation S under the Securities Act) unless registered under the Securities Act or pursuant to an exemption from such registration. There is no intention to register securities of the Company under the Securities Act.

You acknowledge that all industrial and intellectual property rights to this presentation are and shall remain vested in the Company. By attending this presentation or accessing the Materials you shall not acquire any right, title, license to use, or interest in the presentation or the Materials.

All of the trademarks, service marks and logos displayed in the Materials, including but not limited to Biotallys, AGROBODY, EVOCA are registered and unregistered trademarks of the Company or one of its affiliates. Except as expressly provided in the Materials, you may not reproduce, display or otherwise use trademarks without first obtaining the Company’s written permission.

Biotallys and each of their logos are commercial names, trademarks or registered trademarks owned by Biotallys NV.

